News | Leads Implantable Devices | March 29, 2016

St. Jude Medical Announces European Launch of Expanded Quadripolar Pacing Leads

Additional lead sizes and electrode spacing options are designed to more effectively meet the needs of each patient’s unique anatomy.

St. Jude Medical, CE Mark and launch, quadripolar pacing leads

March 29, 2016 — St. Jude Medical Inc. announced CE Mark approval and launch of three new Quartet left ventricular (LV) leads, offering additional electrode spacing options and one new lead shape. The additional spacing combinations are aimed to more effectively target the individual cardiac anatomies of patients who need support from cardiac resynchronization therapy pacemakers (CRT-P) and defibrillators (CRT-D).

“Heart and blood vessel anatomy vary from patient to patient, so having multiple sizes and spacing options with the Quartet quadripolar lead helps me to treat all of my patients in need of cardiac resynchronization therapy. We are now able to place the quadripolar lead in the best possible location for that patient, capturing more cardiac tissue to give heart failure patients the best opportunity to respond,” said Sami Pakarinen, M.D., a cardiologist from Helsinki University Central Hospital in Finland.

Studies have shown that CRT can improve the quality of life for many patients with heart failure. CRT resynchronizes the beating of the heart's lower chambers (ventricles), which often beat out of sync in heart failure patients. The addition of MultiPoint Pacing technology enables physicians to program a single Quartet LV lead to pace multiple sites on the left side of the heart, giving the clinician more choices to improve patient response to therapy and reducing the likelihood of costly and invasive lead revision through a second intervention procedure.

The new leads are designed based on the company’s proven quadripolar LV lead technology and include additional spacing options on two new S-shape and one new double-bend lead designs.

Some of the newly approved products are also magnetic resonance (MR) – conditional, including the Quadra Assura CRT-D and Quadra Assura MP CRT-D with MultiPoint Pacing. Additionally, physicians will be able to quickly customize therapy using the Auto VectSelect Quartet Test, which is designed to automatically guide programming of the most appropriate therapy options available and streamline workflow.

For more information: www.sjm.com


Related Content

News | ACC

March 28, 2026-- At ACC.26, Corcept Therapeutics Inc. presented late-breaking data from its MOMENTUM trial examining the ...

Home April 02, 2026
Home
News | ACC

March 30, 2026 — Helen H. Hobbs, M.D., professor in the Eugene McDermott Center for Human Growth and Development and of ...

Home April 01, 2026
Home
News | ACC

March 30, 2026 — At ACC.26 in New Orleans, Esperion presented two post-hoc analyses from CLEAR Outcomes focused on risk ...

Home April 01, 2026
Home
News | ACC

March 30, 2026 — Partho Sengupta, MD, DM, FACC, FASE, was honored as a 2026 Distinguished Scientist (Translational ...

Home March 31, 2026
Home
News | ACC

March 29, 2026 — Medical AI, a company specializing in artificial intelligence-enabled electrocardiogram (ECG) solutions ...

Home March 31, 2026
Home
News | ACC

March 28, 2026 — Randomized controlled trial (RCT) data presented at the American College of Cardiology (ACC) 2026 and ...

Home March 30, 2026
Home
News | ACC

March 25, 2026 — At the 75th Annual Scientific Session & Expo of the American College of Cardiology (ACC.26) in New ...

Home March 27, 2026
Home
News | ACC

March 18, 2026 — UltraSight will present six clinical studies validating the performance of its UltraSight Echosystem at ...

Home March 27, 2026
Home
News | ACC

March 25, 2026 — At ACC.26, GE HealthCare will showcase some of its latest solutions that support clinicians across the ...

Home March 26, 2026
Home
News | ACC

March 24, 2026 — Physicians and investigators from the Smidt Heart Institute at Cedars-Sinai will present research and ...

Home March 26, 2026
Home
Subscribe Now